Last updated on May 2017

Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Cancer


Brief description of study

Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Cancer

Detailed Study Description

The MR-guided ExAblate Focused Ultrasound study is being conducted to assess the safety and effectiveness of an investigational device for the treatment of prostate cancer.

The ExAblate treatment is a focal treatment where a small portion of the prostate is treated, only where the cancer is located.

The study will enroll 100 patients with intermediate risk, localized, organ confined prostate cancer. For most study patients, this study will last for up to 26 – 30 months. If you qualify for the study, you will receive the ExAblate treatment.

This clinical research study will evaluate the safety and effectiveness of ExAblate for the treatment of intermediate risk, localized, organ confined prostate cancer.

Clinical Study Identifier: TX149745

Find a site near you

Start Over

Weill Cornell Medical Center

Located in: New York, NY USA
  Connect »

Brigham & Women's Hospital

Located in: Boston, MA USA
  Connect »

Sperling Prostate Center

Located in: Delray Beach, FL USA
  Connect »

Henry Ford Hospital:

Located in: Detroit, MI USA
  Connect »

University of Virginia

Located in: Charlottesville, VA USA
  Connect »

University of California Los Angeles

Located in: Los Angeles, CA USA
  Connect »

Mayo Clinic

Located in: Rochester, MN USA
  Connect »

City of Hope

Located in: Duarte, CA USA
  Connect »